The World Health Organisation (WHO) estimates that up to one in ten medicines could be counterfeit in poorer countries. On top of patient safety concerns, this is costing $30bn a year. To combat this issue, the EU will be introducing the Falsified Medicines Directive (EU FMD), which comes into force in February 2019.
Eric Tjoa, owner and CEO of Tjoapack discussed the impact of serialization on the pharmaceutical industry and the challenges it has presented in Packaging News. Alongside other industry experts, he outlines the need for outsourcing at this late stage in order to reach compliance before the EU FMD deadline.
You can read the article in full here.